The Schistosomiasis Market is expected to register a CAGR of 3.1% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Schistosomiasis Market report covers analysis by Site (Intestinal, Urogenital); Drug Type (Praziquantel, Metrifonate, Oxamniquine), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Schistosomiasis Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Schistosomiasis Market Segmentation
Site- Intestinal
- Urogenital
- Praziquantel
- Metrifonate
- Oxamniquine
Strategic Insights
Schistosomiasis Market Growth Drivers- High Prevalence of Schistosomiasis in Endemic Regions: The disease is highly prevalent in the tropical and subtropical regions of the world, especially in sub-Saharan Africa, parts of Asia, and South America. A major driver for the demand for treatment, diagnostics, and prevention is the widespread presence of the disease affecting millions of people every year. Limited access to clean water, poor sanitation, and environmental factors contribute to continuous high infection rates in these regions.
- Government Initiatives and Funding for Schistosomiasis Control: International organizations like WHO and the Bill & Melinda Gates Foundation along with governmental bodies have pumped in lots of resources to eliminate this disease. Many programs undertaken through public awareness regarding sanitation improvement have created an incentive for the demand for schistosomiasis medications, and drugs along with their relevant diagnostic equipment; such as Praziquantel, since these initiatives can increase accessibility along with demanding remedies.
- Improving Healthcare Infrastructure: This can be attributed to enhanced management and cure of diseases. Increasing the scale of health services, which covers primary care, diagnostic tests, and access to drugs, are the driving factors of this market. Control measures for the spreading of schistosomiasis include strategies that make treatment more accessible and affordable.
- More Mass Drug Administration: Mass drug administration (MDA) programs whereby anti-schistosomiasis medications are administered to an entire population of endemic areas, are becoming highly popular. In these programs, the prevalence of the disease would be reduced significantly through large, preventive treatment programs. As a result of widespread support for MDA programs, demands for drugs like praziquantel, as well as new, more effective drugs are on the increase.
- Public-Private Partnership: Public-private partnership is one of the most upcoming trends in the schistosomiasis market. Such collaborations between the pharmaceutical industries, NGOs, and governments have provided easy access to medicines and diagnostic instruments. Public-private partnerships are inevitable for improving the health needs of populations in resource-scarce regions and facilitating the dissemination of drugs essential for underprivileged communities.
- Emphasis on Integrated Approaches to Disease Control: Integrated control programs that combine schistosomiasis treatment with efforts to improve sanitation, water access, and overall public health are becoming more common. Such approaches are viewed as essential for reducing transmission and preventing reinfection. This holistic approach is gaining attention in endemic countries and driving the development of multi-faceted strategies to address the disease.
- Development of a Schistosomiasis Vaccine: The development of an effective vaccine for schistosomiasis is one of the most significant opportunities in the market. Vaccination could be the game-changer in preventing the disease, reducing drug dependency, and eliminating transmission. As research on vaccine candidates goes on, the companies investing in this area can gain a major market share in case a safe and effective vaccine is developed.
- Increasing Access to Diagnostics in Endemic Areas: Improved diagnostic tools, especially those that are affordable, accurate, and easy to use in remote areas, represent a significant opportunity for market growth. Portable and rapid diagnostic tests used in field settings are in high demand because they enable early detection of infections and help guide treatment decisions.
- Pediatric Market for Schistosomiasis Treatment Drugs: While schistosomiasis is a disease present at all ages, there is an incipient need for pediatric-specific drugs from the viewpoint of physiological differences and child-specific medication requirements. Ensuring the development of drugs that are safe, effective, and easy to administer to children stands out as the most significant opportunity for drug firms marketing to the pediatric segment.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Schistosomiasis Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Schistosomiasis Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Schistosomiasis Market are High Prevalence of Schistosomiasis in Endemic Regions, Government Initiatives and Funding for Schistosomiasis Control, and Improving Healthcare Infrastructure
The key future trends of the market are More Mass Drug Administration, Public-Private Partnership, and Emphasis on Integrated Approaches to Disease Control
The leading players operating in the Schistosomiasis Market include Shin Poong Pharma.Co., Ltd., Merck & Co., Inc., Bayer AG.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Drugs For Schistosomiasis Market - By Site
1.3.2 Drugs For Schistosomiasis Market - By Drug Type
1.3.3 Drugs For Schistosomiasis Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DRUGS FOR SCHISTOSOMIASIS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DRUGS FOR SCHISTOSOMIASIS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. DRUGS FOR SCHISTOSOMIASIS MARKET - GLOBAL MARKET ANALYSIS
6.1. DRUGS FOR SCHISTOSOMIASIS - GLOBAL MARKET OVERVIEW
6.2. DRUGS FOR SCHISTOSOMIASIS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. DRUGS FOR SCHISTOSOMIASIS MARKET - REVENUE AND FORECASTS TO 2028 - SITE
7.1. OVERVIEW
7.2. SITE MARKET FORECASTS AND ANALYSIS
7.3. INTESTINAL
7.3.1. Overview
7.3.2. Intestinal Market Forecast and Analysis
7.4. UROGENITAL
7.4.1. Overview
7.4.2. Urogenital Market Forecast and Analysis
8. DRUGS FOR SCHISTOSOMIASIS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
8.1. OVERVIEW
8.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
8.3. PRAZIQUANTEL
8.3.1. Overview
8.3.2. Praziquantel Market Forecast and Analysis
8.4. METRIFONATE
8.4.1. Overview
8.4.2. Metrifonate Market Forecast and Analysis
8.5. OXAMNIQUINE
8.5.1. Overview
8.5.2. Oxamniquine Market Forecast and Analysis
9. DRUGS FOR SCHISTOSOMIASIS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Drugs For Schistosomiasis Market Overview
9.1.2 North America Drugs For Schistosomiasis Market Forecasts and Analysis
9.1.3 North America Drugs For Schistosomiasis Market Forecasts and Analysis - By Site
9.1.4 North America Drugs For Schistosomiasis Market Forecasts and Analysis - By Drug Type
9.1.5 North America Drugs For Schistosomiasis Market Forecasts and Analysis - By Countries
9.1.5.1 United States Drugs For Schistosomiasis Market
9.1.5.1.1 United States Drugs For Schistosomiasis Market by Site
9.1.5.1.2 United States Drugs For Schistosomiasis Market by Drug Type
9.1.5.2 Canada Drugs For Schistosomiasis Market
9.1.5.2.1 Canada Drugs For Schistosomiasis Market by Site
9.1.5.2.2 Canada Drugs For Schistosomiasis Market by Drug Type
9.1.5.3 Mexico Drugs For Schistosomiasis Market
9.1.5.3.1 Mexico Drugs For Schistosomiasis Market by Site
9.1.5.3.2 Mexico Drugs For Schistosomiasis Market by Drug Type
9.2. EUROPE
9.2.1 Europe Drugs For Schistosomiasis Market Overview
9.2.2 Europe Drugs For Schistosomiasis Market Forecasts and Analysis
9.2.3 Europe Drugs For Schistosomiasis Market Forecasts and Analysis - By Site
9.2.4 Europe Drugs For Schistosomiasis Market Forecasts and Analysis - By Drug Type
9.2.5 Europe Drugs For Schistosomiasis Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Drugs For Schistosomiasis Market
9.2.5.1.1 Germany Drugs For Schistosomiasis Market by Site
9.2.5.1.2 Germany Drugs For Schistosomiasis Market by Drug Type
9.2.5.2 France Drugs For Schistosomiasis Market
9.2.5.2.1 France Drugs For Schistosomiasis Market by Site
9.2.5.2.2 France Drugs For Schistosomiasis Market by Drug Type
9.2.5.3 Italy Drugs For Schistosomiasis Market
9.2.5.3.1 Italy Drugs For Schistosomiasis Market by Site
9.2.5.3.2 Italy Drugs For Schistosomiasis Market by Drug Type
9.2.5.4 Spain Drugs For Schistosomiasis Market
9.2.5.4.1 Spain Drugs For Schistosomiasis Market by Site
9.2.5.4.2 Spain Drugs For Schistosomiasis Market by Drug Type
9.2.5.5 United Kingdom Drugs For Schistosomiasis Market
9.2.5.5.1 United Kingdom Drugs For Schistosomiasis Market by Site
9.2.5.5.2 United Kingdom Drugs For Schistosomiasis Market by Drug Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Drugs For Schistosomiasis Market Overview
9.3.2 Asia-Pacific Drugs For Schistosomiasis Market Forecasts and Analysis
9.3.3 Asia-Pacific Drugs For Schistosomiasis Market Forecasts and Analysis - By Site
9.3.4 Asia-Pacific Drugs For Schistosomiasis Market Forecasts and Analysis - By Drug Type
9.3.5 Asia-Pacific Drugs For Schistosomiasis Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Drugs For Schistosomiasis Market
9.3.5.1.1 Australia Drugs For Schistosomiasis Market by Site
9.3.5.1.2 Australia Drugs For Schistosomiasis Market by Drug Type
9.3.5.2 China Drugs For Schistosomiasis Market
9.3.5.2.1 China Drugs For Schistosomiasis Market by Site
9.3.5.2.2 China Drugs For Schistosomiasis Market by Drug Type
9.3.5.3 India Drugs For Schistosomiasis Market
9.3.5.3.1 India Drugs For Schistosomiasis Market by Site
9.3.5.3.2 India Drugs For Schistosomiasis Market by Drug Type
9.3.5.4 Japan Drugs For Schistosomiasis Market
9.3.5.4.1 Japan Drugs For Schistosomiasis Market by Site
9.3.5.4.2 Japan Drugs For Schistosomiasis Market by Drug Type
9.3.5.5 South Korea Drugs For Schistosomiasis Market
9.3.5.5.1 South Korea Drugs For Schistosomiasis Market by Site
9.3.5.5.2 South Korea Drugs For Schistosomiasis Market by Drug Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Drugs For Schistosomiasis Market Overview
9.4.2 Middle East and Africa Drugs For Schistosomiasis Market Forecasts and Analysis
9.4.3 Middle East and Africa Drugs For Schistosomiasis Market Forecasts and Analysis - By Site
9.4.4 Middle East and Africa Drugs For Schistosomiasis Market Forecasts and Analysis - By Drug Type
9.4.5 Middle East and Africa Drugs For Schistosomiasis Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Drugs For Schistosomiasis Market
9.4.5.1.1 South Africa Drugs For Schistosomiasis Market by Site
9.4.5.1.2 South Africa Drugs For Schistosomiasis Market by Drug Type
9.4.5.2 Saudi Arabia Drugs For Schistosomiasis Market
9.4.5.2.1 Saudi Arabia Drugs For Schistosomiasis Market by Site
9.4.5.2.2 Saudi Arabia Drugs For Schistosomiasis Market by Drug Type
9.4.5.3 U.A.E Drugs For Schistosomiasis Market
9.4.5.3.1 U.A.E Drugs For Schistosomiasis Market by Site
9.4.5.3.2 U.A.E Drugs For Schistosomiasis Market by Drug Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Drugs For Schistosomiasis Market Overview
9.5.2 South and Central America Drugs For Schistosomiasis Market Forecasts and Analysis
9.5.3 South and Central America Drugs For Schistosomiasis Market Forecasts and Analysis - By Site
9.5.4 South and Central America Drugs For Schistosomiasis Market Forecasts and Analysis - By Drug Type
9.5.5 South and Central America Drugs For Schistosomiasis Market Forecasts and Analysis - By Countries
9.5.5.1 Argentina Drugs For Schistosomiasis Market
9.5.5.1.1 Argentina Drugs For Schistosomiasis Market by Site
9.5.5.1.2 Argentina Drugs For Schistosomiasis Market by Drug Type
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. DRUGS FOR SCHISTOSOMIASIS MARKET, KEY COMPANY PROFILES
11.1. SHIN POONG PHARMA.CO., LTD.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. MERCK AND CO., INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BAYER AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Shin Poong Pharma.Co., Ltd.
2. Merck & Co., Inc.
3. Bayer AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For